What diseases can benefit from GcMAF therapy?
Gc-MAF macrophage activation therapy is indicated in the treatment of any diseases where there is immune disfunction or where the immune system is compromised, such as:
Cancer, Autoimmune diseases, Epstein-Barr Virus (EBV), Hepatitis B virus (HCV), Herpes Simplex virus (HSV), Cystitis, Hepatitis C virus (HBV), Tuberculosis, Urinary tract infection (UTI), Autism, Pneumonia infection, Endometriosis, Chronic Fatigue Syndrome (CFS), Lyme disease, IgA deficiency disorder, Myalgic Encephalomyelitis (ME), Mycobacteria infections, Influenza virus, Multiple sclerosis (MS), Fibromyalgia, Parkinson's disease, Lupus, HIV AIDS.
Are there any side effects with GcMAF?
GcMAF has been clinically demonstrated to be largely free of any side effects in the great majority of patients. Only low grade fever or inflamtion has been observed in only about 1 out of 100 patients using GcMAF, but these were short-term effects that are significantly less than occur with most other immunotherapies. In small numbers of patients local injection site skin reactions occur which can be easily treated with a local non-steroidal anti-inflammatory patch.
Can GcMAF be used with other conventional therapies?
Generally, yes. GcMAF can be safely used with a wide variety of other standard treatments and drugs to improve their effect. We refer to this as multimodality integrative medicine. Some therapies for cancer such as chemotherapy will reduce immune activity which will have some impact on GcMAF, however chemotherapy effectiveness can be increased in combination with GcMAF. Radiation for cancer has less negative impact on the immune system and the cancer killing effects helps macrophages to target the tumors and destroy it.
Подробнее: Can GcMAF be used with other conventional therapies?
Latest News
- Buy GcMAF
- Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice
- Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation
- Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients
- Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer
Most Read Articles
- Buy GcMAF
- Are there any side effects with GcMAF?
- Can GcMAF be used with other conventional therapies?
- What diseases can benefit from GcMAF therapy?
- Nagalase Blood Test Labs
- Nagalase Blood Test
- GcMAF-терапия при аутизме
- GcMAF als ein immuntherapeutischer Herangehensweise zur Krebsbekämpfung
- Frequently Asked Questions
- The Yamamoto Papers
Contact Us
Cyto Innovations Ltd
Suite 36, 88-90 Hatton Gardens
Holborn
London
EC1N 8PG
Tel: 0044 77166 97216
Email: info@gc-maf.de
Company Registration No.: 08460429